Table 1

Patient characteristics

Symptom free controls (n=19)ACPA positive arthralgia (n=21)ACPA positive RA (n=22)
Age (years) (mean±SD)46.2±11.847.9±7.953.7±15.9
Female sex (n (%))15 (78.9)17 (81.0)12 (54.5)
Symptom duration at MRI (weeks) (median (IQR))n/a34.5 (15.3–114.5)20 (11–37)
Onset of symptoms (n (%))
 (Sub) acuten/a6 (28.6)7 (31.8)
 Gradualn/a15 (71.4)15 (68.2)
Morning stiffness (min) (median (IQR))n/a30 (5–60)60 (45–120)
Swollen joint count (median (IQR))005 (3–12)
Tender joint count (median (IQR))02 (1–3)6 (5–11)
ACPA level (median (IQR))n/a326 (94–340)182 (87–324.3)
RF positivity (n (%))n/a15 (71.4)19 (86.4)
RF level (median (IQR))n/a22 (10.5–120)20 (11.5–91)
  • Sixty-eight tender joint count and 66 swollen joint count were performed. Symptom duration refers to the period between the first symptom onset of any joint and the MRI date.

  • ACPA, anticitrullinated peptide antibodies; n/a, not applicable; RA, rheumatoid arthritis; RF, rheumatoid factor.